Quality Scorecard - Colonoscopy Screening to Prevent Colorectal Cancer
What is measured?
Quality in colonoscopy screening can be measured by the adenoma detection rate or ADR. This is the percentage of patients who had at least one adenoma detected during a screening colonoscopy. An adenoma is a type of polyp that has a high potential to become colorectal cancer.
Currently, recommendations from multiple medical societies for average-risk patients suggest an ADR of at least 20 percent for women and at least 30 percent for men. At PAMF, our doctors have an ADR of 33 percent for average-risk women and 42 percent for average-risk men. This is an 18 percentage point increase in adenoma detection for women, and a 17 percentage point increase in adenoma detection for men, as compared to the national benchmark.
According to a recent study published in the New England Journal of Medicine, each 1 percent increase in the adenoma detection rate is associated with a 3 percent decrease in colorectal cancer risk.
Why does PAMF's ADR matter?
Colonoscopy is the primary screening tool for colorectal cancer. The ADR is tightly linked with the prevention of colon cancer, since any adenomas that are missed during colonoscopy could potentially become cancerous in the interval between screenings. This is why a higher ADR generally means a lower risk of cancer within the next 5 to 10 years after the screening.
Facts about colonoscopies and ADR
- Current health maintenance guidelines recommend colonoscopy for men and women every ten years beginning at age 50.
- Individuals with a family history of colon cancer or advanced polyps before age 60 may need to be screened earlier or more frequently.
Here is how PAMF's ADR compares to the national performance benchmark:
Percent patients by sex, with screening colonoscopies when one or more adenomas were detected vs. the nation benchmark (12,464 patients, 2015)
How is data gathered?
Data without personal identification is excerpted from patient records within 60 days of the colonoscopy procedure. Patients are considered average-risk if they had a screening colonoscopy only, have no personal or family history of colorectal cancer or polyps, and do not have Crohn’s disease or ulcerative colitis.